Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome

scientific article published in May 2005

Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/GPS.1306
P698PubMed publication ID15852458

P2093author name stringAdams C
Prasher VP
Fung N
P2860cites workReview of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability populationQ35813930
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.Q43938550
Down syndrome and Alzheimer disease: response to donepezilQ44063664
Cholinergic therapy for Down's syndromeQ77310745
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectAlzheimer's diseaseQ11081
dementiaQ83030
P304page(s)496-497
P577publication date2005-05-01
P1433published inInternational Journal of Geriatric PsychiatryQ6051406
P1476titleRivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome
P478volume20

Reverse relations

cites work (P2860)
Q33726997Certainty of genuine treatment increases drug responses among intellectually disabled patients
Q90531305Challenges faced in managing dementia in Alzheimer's disease in patients with Down syndrome
Q37217895Cholinergic components of frontal lobe function and dysfunction
Q38865366Dementia in Down's syndrome
Q48287894Down syndrome: the brain in trisomic mode
Q38312346Pharmacological management of behavioral and psychiatric symptoms in older adults with intellectual disability
Q22252965Rivastigmine for dementia in people with Down syndrome
Q85849603Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study
Q35087290Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study
Q51930325The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome.
Q33770940Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial

Search more.